Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin Flexpro, is a growth hormone presented as a recombinant protein for subcutaneous use. It is prescribed to treat growth hormone deficiency and related growth disorders in children and adults, helping to normalize growth and metabolic processes.

GNH USA supplies Norditropin Flexpro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products, ensuring product integrity from manufacture to delivery.

Norditropin Flexpro (somatropin) is used in endocrine therapy to address conditions characterized by insufficient endogenous growth hormone. - Growth hormone deficiency: Improves linear growth in children and restores normal metabolic function in adults with GH deficiency. - Turner syndrome: Increases height velocity and helps achieve near‑normal adult stature in girls with this chromosomal disorder. - Prader‑Willi syndrome: Enhances growth and body composition, supporting better physical development in affected individuals. - Chronic renal insufficiency: Promotes growth in pediatric patients with renal disease where GH deficiency contributes to short stature.

Somatropin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the injection site. - Headache: transient headache reported in some patients. - Joint stiffness: occasional arthralgia or reduced joint mobility. - Edema: peripheral swelling, especially in the lower extremities. - Hyperglycemia: elevated blood glucose levels, particularly in predisposed individuals.

Serious or Rare Side Effects: - Intracranial hypertension: signs include severe headache, visual disturbances, and papilledema. - Slipped epiphysis: premature closure of growth plates leading to bone deformities. - Allergic reactions: rash, urticaria, or anaphylaxis in rare cases. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.

Prior to initiating Norditropin Flexpro, clinicians should consider several safety measures to minimize risks. - Monitor IGF‑1 levels: adjust dose based on serial measurements to avoid excess exposure. - Screen for diabetes: assess fasting glucose and HbA1c before and during therapy. - Evaluate for intracranial hypertension: watch for persistent headaches or visual changes. - Avoid in active malignancy: growth hormone may stimulate tumor growth. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Glucocorticoids: may blunt the anabolic effects of growth hormone. - Insulin: somatropin can reduce insulin sensitivity, requiring dose adjustments. - Oral estrogen therapy: can diminish IGF‑1 response, potentially reducing efficacy.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: GH therapy may increase thyroid hormone requirements. - Diuretics: may exacerbate fluid retention and edema. - Antidiabetic agents: monitor glucose control as GH may raise blood sugar.